BiotechTube

VAY736

Phase 2/3Completed
0 watching 0 views this week📈 Rising
65
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Autoimmune Hepatitis

Conditions

Autoimmune Hepatitis

Trial Timeline

Feb 15, 2018 → Dec 17, 2025

NCT ID
NCT03217422

About VAY736

VAY736 is a phase 2/3 stage product being developed by Novartis for Autoimmune Hepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03217422. Target conditions include Autoimmune Hepatitis.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (5)

NCT IDPhaseStatus
NCT05349214Phase 3Active
NCT05350072Phase 3Active
NCT03217422Phase 2/3Completed
NCT02962895Phase 2Completed
NCT02137889Phase 1Terminated

Competing Products

20 competing products in Autoimmune Hepatitis

See all competitors
ProductCompanyStageHype Score
SatralizumabChugai PharmaceuticalPhase 3
77
SHR0302 quick release tablets + SHR0302 sustained-release tabletsJiangsu Hengrui MedicinePhase 1
33
HR19042 Capsule, Tarpeyo®, Budenofalk®Jiangsu Hengrui MedicinePhase 1
33
HR19042 CapsulesJiangsu Hengrui MedicinePhase 2
52
Enteric-coated Mycophenolate SodiumNovartisPhase 3
77
Ianalumab + PlaceboNovartisPhase 3
77
remibrutinibNovartisPhase 1
33
RO7049665RochePhase 2
52
rituximab (Mabthera®) + PlaceboRochePhase 3
77
NovoMix 30 + Tablet treatmentNovo NordiskPre-clinical
22
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)Swedish Orphan BiovitrumPhase 2
51
branebrutinib + abatacept + branebrutinib placeboBristol Myers SquibbPhase 2
51
BMS-986165Bristol Myers SquibbPhase 1
32
NivolumabBristol Myers SquibbPhase 1
32
Fludarabine + Cyclophosphamide + TocilizumabBristol Myers SquibbPhase 1
32
BMS-986165 + RosuvastatinBristol Myers SquibbPhase 1
32
SAR445088SanofiPhase 1
32
BIVV020SanofiPhase 1
32
rilzabrutinibSanofiPhase 2
51
rilzabrutinib + placeboSanofiPhase 3
76

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85